Prot#NLY01-PD-1: Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 36 Weeks of Treatment with NLY01 in Early-stage Parkinson’s Disease

Project: Research project

Project Details

StatusFinished
Effective start/end date8/11/20 → 8/31/24

Funding

  • Rho, Inc (Prot# NLY01-PD-1 // Prot# NLY01-PD-1)
  • Neuraly, Inc. (Prot# NLY01-PD-1 // Prot# NLY01-PD-1)